YUTIQ implant for chronic non-infectious eye inflammation
Part of Eyes & vision clinical trials.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 70, and in generally good health
- You have uveitis in one or both eyes that is not caused by an infection
- Your eye inflammation is active right before YUTIQ treatment (for example, cells in the front of the eye, haze in the eye fluid, leaking on a dye test, swelling in the back of the eye, or frequent relapses)
- You stopped steroid or immune-suppressing eye treatments within 3 months after a prior YUTIQ injection
- You can safely have eye doctors examine your retina and vitreous (no serious blockage from cornea/lens clouding or bleeding)
- You can’t have certain recent eye steroid injections or prior YUTIQ/Retisert/ILUVIEN/other similar implants within the listed time windows
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether receiving two YUTIQ injections works better than a sham (fake) treatment for long-lasting inflammation inside the back part of the eye. It is meant to reduce ongoing “posterior segment” inflammation and improve comfort and eye health when prior steroid treatments have helped but the inflammation keeps coming back.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial tests whether minocycline, an antibiotic that can also reduce inflammation, helps improve chronic autoimmune uveitis and protect vision. It may help by lowering ongoing immune irritation that damages the eye.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
This trial studies adalimumab to treat a rare, fast-onset eye inflammation called Vogt-Koyanagi-Harada disease. It may help people who can’t use strong steroid treatments or whose disease is not improving quickly with them.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.